Evaluating the impact of extended dosing intervals on mRNA COVID-19 vaccine effectiveness in adolescents.

ABSTRACT:

Background

Extending the dosing interval of a primary series of mRNA COVID-19 vaccination has been employed to reduce myocarditis risk in adolescents, but previous evaluation of impact on vaccine effectiveness (VE) is limited to risk after second dose.

Methods

We quantified the impact of the dosing interval based on case notifications and vaccination uptake in Hong Kong from January to April 2022, based on calendar-time proportional hazards models and matching approaches.

Results

We estimated that the hazard ratio (HR) and odds ratio (OR) of infections after the second dose for extended (28 days or more) versus regular (21-27 days) dosing intervals ranged from 0.86 to 0.99 from calendar-time proportional hazards models, and from 0.85 to 0.87 from matching approaches,

SUBMITTER: Tsang TK 

PROVIDER: S-EPMC11396738 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature